



Published in final edited form as:

Psychosom Med. 2011 ; 73(9): 724–730. doi:10.1097/PSY.0b013e318235be76.

Biobehavioral Factors and Cancer Progression: Physiological Pathways and Mechanisms

Susan K. Lutgendorf, Ph.D.^{1,2} and Anil K. Sood, M.D.³

¹Department of Psychology, Obstetrics and Gynecology, and Urology, University of Iowa

²Holden Comprehensive Cancer Center, University of Iowa

³Departments of Gynecologic Oncology and Cancer Biology, UT MD Anderson Comprehensive Cancer Center

Abstract

Epidemiological evidence increasingly has supported the role of biobehavioral risk factors such as social adversity, depression, and stress in cancer progression. This review describes *in vitro*, *in vivo*, and clinical studies demonstrating relationships between such processes and pathways involved in cancer progression. These include effects on the cellular immune response, angiogenesis, invasion, anoikis, and inflammation. Biobehavioral factors have been shown to contribute to the cross-talk between tumor and host cells in the tumor microenvironment and stress effects on host cells such as macrophages appear to be critical for many pathways involved in tumor progression. Some effects are bi-directional, in that tumor derived inflammation appears to affect central nervous system processes, giving rise to vegetative symptoms and contributing to dysregulation of the HPA axis with downstream effects on inflammatory control. Findings to date are reviewed and fruitful areas for future research are discussed.

Keywords

Biobehavioral; stress; social support; oncology; angiogenesis; anoikis; beta-adrenergic; glucocorticoid

Ever since the time of the ancient Greeks, there has been an interest in the relationship between psychological states and cancer (1). Epidemiologic studies have highlighted several key psychological factors related to both cancer initiation (development of cancer in patients with no previous tumor) and progression (expansion of disease in patients with existing cancers). The most commonly studied factors have been chronic stress, depression/distress, and social support/isolation. Epidemiologic data supporting a potential role of psychological factors as related to cancer initiation have been relatively equivocal (2-4), with the most consistent evidence pointing to a relationship of cancer incidence with severe life events, severe distress, or long term depression (5-6). A more consistent association has been observed between psychosocial risk factors such as depression (7-9), distress (10), trauma history (11), social isolation (12-14) and more rapid cancer progression. Recent meta-analyses have linked depression (15), stressful life events (10,16), and social isolation (17) with poorer survival in cancer patients. Although not all findings are consistent (18-19), the predominance of epidemiological evidence supports a relationship between psychosocial

factors and cancer progression. Thus this review will focus on data related to cancer progression.

Model of the socio-environmental macroenvironment and cancer progression

A conceptual model has been proposed linking socio-environmental factors in the “macroenvironment” and cancer progression (20). According to this model, central nervous system (CNS) perceptions of threat from environmental stressors such as negative life events, socioeconomic burden, relationship difficulties, social isolation, etc. interact with an individual’s characteristic attitudes, perceptions, and coping abilities, resulting in conditions such as perceived stress, distress, loneliness, etc. These states, particularly when experienced chronically, lead to downstream activation of neuroendocrine pathways including the autonomic nervous system and the hypothalamic pituitary adrenal (HPA) axis. Catecholamines, glucocorticoids and other stress hormones and neuropeptides (e.g., oxytocin, dopamine) are released *via* the brain, sympathetic nervous system (SNS), and/or the HPA axis. Neuroendocrine stress hormones in the tumor microenvironment assert a systemic influence on tumor growth. Psychosocial factors such as active coping, resilience, optimism, and social support may act to buffer the elicitation of the stress response. It should be noted that although psychology has elaborated definite distinctions between constructs such as “stress”, “distress”, “depression”, and “social isolation”, at this point in development of biobehavioral oncology research, the biological signatures of these various constructs have not been well differentiated with respect to processes at the tumor level. The pre-clinical studies generally use stress-related paradigms. Thus, we have adopted the relatively imprecise approach of describing constructs like “depression” and “social isolation” along with “stress” as “biobehavioral risk factors” to convey the general phenomenon that biobehavioral processes appear to systematically impact a variety of important hallmarks of cancer biology. As most of the emerging work described below has involved the SNS and the HPA axis, discussion will focus on these two stress response systems; however it is likely that a variety of other neuroendocrine hormones may also influence the biological processes described below.

Early research examining CNS effects on cancer predominantly focused on down-regulation of the immune response as a potential mediator of impaired surveillance for metastatic spread (21-25). Other work focused on stress effects on DNA repair (26,27). Given the unlikely role of a singular system in explaining the biological effects of stress pathways on cancer progression, over the last 10 years, the focus of mechanistic biobehavioral oncology research has broadened to include examination of the effects of stress on a) tumor angiogenesis; b) invasion and anoikis; c) stromal cells in the tumor microenvironment, and d) inflammation.

Biobehavioral Factors and the Cellular Immune Response in Cancer Progression

Substantial evidence has demonstrated that negative psychosocial states, such as chronic stress, depression, and social isolation, are associated with down-regulation of the cellular immune response, mediated largely by adrenergic and glucocorticoid signaling (28-30). For example, among breast cancer patients following surgery, low social support and distress have been linked with decrements in indicators of cellular immunity, including impaired NK cell cytotoxicity (31-33), blunted T-cell production of TH₁ vs. TH₂ cytokines (34), and decreased T-cell proliferative response to mitogens (33). Depression has also been associated with a poorer cellular immune response to specific antigens in breast cancer

patients (35). It should be noted, however, that not all findings have been consistent in this literature (e.g., 36).

Tumors have well-developed escape mechanisms by which they interfere with immune cell signaling and thus evade recognition and destruction by the immune response (37,38). Thus the immune response in the tumor microenvironment is substantially down-regulated compared to that in peripheral blood. We therefore considered whether stress-related influences would still operate within the tumor microenvironment. Among ovarian cancer patients at the time of surgery, NK cell activity in tumor infiltrating lymphocytes (TIL) was diminished by more than 50%, compared to NK cell activity in lymphocytes isolated from peripheral blood, reflecting substantial down-regulation. Nevertheless, biobehavioral factors were related to the cellular immune response in TIL. Specifically, social support was related to greater NK cell activity in both peripheral blood and TIL, whereas distress was associated with blunted NK cell activity in TIL and poorer T-cell production of TH₁ vs. TH₂ cytokines in peripheral blood, ascites, and TIL (39,40). These findings suggest that biobehavioral risk factors do have some association with immune activity in the tumor microenvironment, and underscore the importance of examining associations between biobehavioral factors and immune cells directly in the tumor microenvironment.

One issue that bears further comment is the extent to which relationships with markers of the immune response are predictive of disease recurrence and survival. This question has been difficult to investigate due to the large sample size and relatively extensive follow-up required. One study reported that depressed patients with hepatobiliary carcinoma had lower NK cell numbers and shorter survival compared to their non-depressed counterparts, and that NK cell count mediated the relationship between depression and survival (7). However, in general the extent to which stress-related changes in the immune response are relevant for recurrence and survival is still unclear, and biobehavioral survival studies among breast cancer patients have not reported a mediating role for NK cell activity (23, 41).

Pre-clinical experimental studies with animal models have demonstrated similar patterns. For example, stress-induced release of catecholamines and prostaglandins, particularly in the peri-surgical period, have been shown to suppress key components of the cellular immune response, including NK cell activity, which may allow for more aggressive course of disease (42-47).

Angiogenesis and Invasion

Cancer-related mortality largely results from the spread of cancer cells from the primary tumor to other sites in the body, a process called metastasis. Successful metastatic spread requires several sequential steps, including angiogenesis, proliferation, invasion, embolization, and colonization of a new secondary site (48). Many of these steps involve complex signaling interactions with surrounding cells. Stress response pathways have now been shown to influence many parts of this cascade including activities of both stromal and tumor cells. (Figure 1).

Tumor growth and metastatic spread is dependent on development of adequate vascularization, a process called angiogenesis. This process is tightly controlled by a variety of positive and negative factors secreted by both tumor and host cells in the tumor microenvironment (49,50). Angiogenesis promoting factors include vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor alpha (TNF α) as well as a variety of other molecules (51,52). *In vitro*, *in vivo*, and clinical studies have demonstrated links between biobehavioral factors and angiogenic pathways. For example, among ovarian cancer patients at the time of surgery, higher levels of social support were associated with lower levels of VEGF both in serum (53) and in tumor tissue

(54). Similarly, among colon cancer patients, loneliness was related to higher levels of tumor VEGF at the time of surgery (55), and depression and poor quality of life were associated with higher serum VEGF, both pre-surgically and 6 weeks post-surgery (56). Each of these studies controlled for relevant clinical variables. *In vitro* experiments in ovarian, melanoma, myeloma and nasopharyngeal cancer cell lines have demonstrated that norepinephrine (NE) and the β -agonist isoproterenol profoundly stimulated expression of VEGF, which was blocked by the beta-blocker propranolol (57-61). Further support for these pathways has come from pre-clinical experiments with orthotopic mouse models of ovarian cancer. Both chronic restraint stress and surgical stress have been shown to increase ovarian tumor weight and invasiveness, changes which were mediated by NE-driven increases in VEGF and angiogenesis (61,62). These effects were completely blocked by propranolol, a non-specific β -blocker, thus confirming the role of adrenergic signaling underlying these effects. Social isolation has been shown to have similar effects on tumor weight and invasiveness (61).

IL-6 is another key cytokine that plays a key role in tumor angiogenesis, attachment, and invasion. It is produced by tumor cells and tumor associated macrophages (TAM) (63,64). Elevated IL-6 levels were observed in both plasma and ascites (the malignant effusions surrounding tumors) in advanced stage ovarian cancer patients with low levels of social support, thus paralleling the VEGF findings described above (65). Stress hormones such as NE have been shown to induce production of IL-6 and IL-8 by ovarian cancer and melanoma cells (59,63), demonstrating effects of stress response pathways on tumor signaling mechanisms. Consistent with these findings, we have observed elevated levels of tumor, but not plasma, NE among patients with low levels of social support suggesting the possibility that these social support findings may be adrenergically mediated at the tumor level (66).

The ability of tumor cells to detach from the primary tumor, invade through the basement membrane and enter the vascular system is another critical step in the metastatic cascade. Matrix metalloproteinases (MMPs) are enzymes secreted by both tumor and stromal cells that facilitate the breakdown and remodeling of the extracellular matrix, thus enabling both local and distal tumor spread (67). Stress hormones promote the migration and invasion of tumor cells in multiple ways, including stimulation of MMP production by both stromal and tumor cells. Levels of NE commensurate with those that would be observed during the stress response have been shown to increase the *in vitro* invasive potential of ovarian cancer cells by 89% to 198%, a process that was blocked by propranolol (68). This effect was mediated by increased MMP-2 and MMP-9 levels in response to NE (68). Similar biological effects have been reported in several other tumor types including colon and head and neck cancers (58,69-71).

Stress effects on anoikis

Cells other than hematopoietic cells are anchorage-dependent and normally survive only when adhering to the extracellular matrix (ECM). Anoikis is the normal process of programmed cell death (apoptosis) occurring when anchorage-dependent cells become separated from the ECM. Cancer cells acquire the ability to resist anoikis, thus enhancing their ability to migrate, re-attach, and establish themselves in secondary sites (72,73). Catecholamines were found to protect ovarian cancer cells from anoikis, both *in vitro* and *in vivo*. These effects were mediated by focal adhesion kinase (FAK), a tyrosine kinase that promotes cell adhesion, which demonstrated increased activation (phosphorylation of pFAK^{Y397}) in response to NE. Clinically, elevated levels of pFAK^{Y397} were observed in the tumor tissue of ovarian cancer patients reporting depression and those with higher levels of tumor NE. Furthermore, phosphorylated FAK was linked to poorer overall survival in these

patients (74). These data demonstrate another pathway by which beta-adrenergic signaling can promote metastatic progression of cancer.

Stress effects on stromal cells in the tumor microenvironment

Tumor growth is to a large extent shaped and promoted or inhibited by signaling between tumor cells and the cells of the microenvironment. In addition to effects of stress hormones on tumor cells, there are marked effects on host cells such as macrophages in the tumor microenvironment. Monocytes are drawn to the tumor microenvironment by tumor-derived chemotactic factors and then differentiate into macrophages. However, under the influence of the pro-inflammatory microenvironment, macrophages are induced to shift from their phagocytic phenotype to a pro-tumor phenotype that produces tumor promoting factors such as VEGF and MMPs, while simultaneously down-regulating the cellular immune response by production of immunosuppressive cytokines such as IL-10 and TGF β (75-78). TAMs are thus directly involved in promoting angiogenesis, tumor proliferation, invasion, metastases, and down-regulation of adaptive immunity. TAM infiltration is also associated with poorer survival (79-81). Both NE and cortisol have been shown to increase production of MMP-9 from monocyte derived macrophages (54). In a pre-clinical orthotopic model of mammary cancer, stress-induced neuroendocrine activation had minimal effects on the primary tumor but showed profound effects on metastatic spread of the tumor to distant sites. These effects were mediated by β -adrenergic effects on macrophages which induced changes in tumor gene expression supporting metastasis along with macrophage differentiation to a tumor supporting phenotype (M2). These effects were blocked by propranolol as well as by suppression of macrophage activities. These findings demonstrate stress effects on tumor metastatic spread *via* tumor-macrophage signaling (82). In ovarian cancer patients, biobehavioral risk factors that have been associated with higher NE levels, such as depression and stress (83) have been related to increased TAM secretion of MMP-9 (54). Thus, stress-related effects on TAM may have important implications for tumor progression, by promoting a microenvironment that favors tumor growth

Biobehavioral risk factors and tumor gene expression

Biobehavioral profiles have been linked to modulation of gene expression in pathways related to tumor progression in ovarian cancer. Tumors from ovarian cancer patients with high levels of depression and low social support (high risk) were compared to those of patients reporting low levels of depression and high social support (low risk) and matched for histology, stage, grade, and age. Compared their low risk counterparts, tumors from high risk patients showed over 200 upregulated gene transcripts, many of which are involved in tumor progression pathways (e.g., CREB, NF κ B, STAT, and ELK1). Furthermore, high risk patients demonstrated elevated levels of intratumoral, but not plasma, NE. These findings point to a distinctive gene expression fingerprint in primary ovarian tumors of patients with high depression and low social support, with beta adrenergic signal transduction as a likely mediator of these relationships (84).

Glucocorticoid Dynamics and Cancer Progression

The previous sections highlight the role of adrenergic pathways in tumor progression. However, glucocorticoids can directly mediate processes promoting tumor growth as well. Cortisol has been shown to stimulate growth of prostate cancer cells (85) and to enhance proliferation of human mammary cancer cells by nearly two-fold (86). Additionally glucocorticoids have been shown to directly enhance a survival pathway in mammary cancer cells (87) and to down regulate expression of DNA repair genes (88). Glucocorticoids are also known to activate survival genes in cancer cells, which could inhibit chemotherapy-induced apoptosis (89-91). These effects may be relevant in the context of pharmacological

glucocorticoids that are given as a part of many chemotherapy regimens. In a murine breast cancer model, social isolation induced an elevated corticosterone stress response, greater tumor burden and alterations in gene expression in metabolic pathways that are known to contribute to increased tumor growth (92). Glucocorticoids are also known to inhibit the cellular immune response and thus are thought to decrease immunosurveillance in the context of cancer (93-95). Thus, glucocorticoids have direct effects on tumor growth and development and resistance to chemotherapy as well as effects on immunosurveillance.

Biobehavioral Factors and Inflammation

Inflammatory processes are common in epithelial tumors, and inflammation serves as a tumor initiator and promoter (96,97). Both tumor cells and TAMs produce substantial levels of inflammatory cytokines, particularly IL-6 (97). Inflammatory cytokines are also produced following cancer treatments such as radiation. Such tumor- or treatment-derived pro-inflammatory cytokines can potentially activate CNS pathways, evoking a syndrome of “sickness behaviors” composed of behavioral and affective responses that mimic flu-like vegetative symptoms (98-100). Pre-clinical studies have now shown that presence of tumor in itself can induce elevations in peripheral as well as central pro-inflammatory cytokines, as well as vegetative depressive-like behaviors (101-2). In clinical samples, fatigued breast cancer survivors have been shown to have chronic elevations in peripheral inflammatory markers accompanied by lower levels of serum cortisol and flatter diurnal cortisol slopes (103-106). Fatigue and debility in ovarian cancer patients have been associated with cortisol dysregulation, in particular, with elevated levels of nocturnal cortisol (106). These findings suggest a tumor-to-brain pathway, in which tumor and treatment-derived pro-inflammatory cytokines may contribute to chronic inflammation, ultimately resulting in sickness behaviors. It is also quite possible that chronic inflammation elicits increased cortisol production for inflammatory control, thereby contributing to HPA axis dysregulation (107-109).

Conclusions and Future Directions

There is converging evidence from *in vitro*, *in-vivo*, and clinical studies, reviewed in brief above, that biobehavioral and stress-related processes are linked with critical elements of the metastatic cascade in both animal and human models. Contributions of systemic factors such as stress hormones to the signaling between tumor and stromal cells appears to be a key factor in modulating downstream pathways, with important implications for progression. This burgeoning area of research is beginning to reveal a coherent picture of physiological pathways implicated in cancer progression that are sensitive to modulation by neuroendocrine and stress-related pathways.

However, there are many important questions that still need to be addressed. Much of the research described above has focused on ovarian or breast cancer patients and pre-clinical models of ovarian and mammary cancer. It will be important to determine if similar processes are evidenced in other cancers, for example in non-solid tumors such as leukemia and lymphomas. Additionally, further specification of the downstream effects of particular psychological constructs is needed at the tumor level. In the clinical literature, lack of perceived social support is a factor that emerges repeatedly in associations with biological variables related to cancer progression, and social isolation has shown similar effects in the preclinical literature. Understanding what it is about social relationships that underlies these associations will be important in future research.

Additional questions include the following: How much stress, in terms of thresholds or chronicity, is needed to modulate tumor-related pathways? Are there windows of treatment

(e.g., after surgery, after completion of treatment, after recurrence) when effects of biobehavioral risk factors might be most important? What are interactions of biobehavioral factors with diet, toxins, and metabolic factors or factors related to gender, race and ethnicity? Do biobehavioral risk factors promote conditions that favor cancer recurrence? To what extent do effects of biobehavioral factors on the tumor microenvironment influence disease progression and survival? The relationship between depression and FAK in light of the link between high FAK and poor ovarian cancer survival discussed above is suggestive in this respect. However, further examination of the clinical implications of these biobehavioral-disease marker relationships will be important in future research.

These findings highlight the importance of translational research to identify pathways relevant for biobehavioral influences on cancer biology. Understanding the mechanisms by which biobehavioral signaling can modulate fatigue, pain, and cognitive symptoms as well as influence the effectiveness of conventional therapies are important directions for future research. Pharmacological approaches including beta-blockers, antidepressants, and anti-inflammatory agents are potentially reasonable candidates for testing in light of the findings discussed above. Psychosocial, mind-body, and complementary interventions may also modulate stress-related pathways implicated in tumor progression. A better understanding of biobehavioral mechanisms involved in cancer progression may help the development of personalized therapy by helping to characterize patients most likely to benefit from innovative intervention strategies.

Acknowledgments

This research was funded in part by support from NIH grants CA88293, CA104825, and [CA140933](#) to SL, NIH grants CA110793, CA109298 to AKS, The University of Texas M.D. Anderson Cancer Center Ovarian Cancer SPORE (P50 CA083639) and the Ovarian Cancer Research Fund, Inc. Program Project Development Grant.

Abbreviations

SNS	sympathetic nervous system
HPA	hypothalamic pituitary adrenal
ECM	extracellular matrix
MMP	matrix metalloproteinase
CNS	central nervous system
NK	natural killer cell
TH1	T helper 1
TH2	T-helper 2
TIL	tumor infiltrating lymphocytes
VEGF	vascular endothelial growth factor
IL-6	interleukin-6
IL-8	interleukin-8
TNFα	tumor necrosis factor alpha
NE	norepinephrine
TAM	tumor associated macrophage
FAK	focal adhesion kinase

IL-10	interleukin 10
TGF-β	tumor growth factor beta
CREB	cyclic AMP response element-binding
NFκB	nuclear factor kappa beta
STAT	signal transducers and Activators of Transcription protein

References

1. Brock, AJ. Greek medicine: being extracts illustrative of medical writers from Hippocrates to Galen. JM Dent and Sons; London, England: 1929.
2. Bleiker EMA, van der Ploeg HM, Hendriks JHCL, Adèr HJ. Personality Factors and Breast Cancer Development: a Prospective Longitudinal Study. *J Nat Cancer Inst.* 2008; 88:1478–1482. [PubMed: 8841023]
3. Cassileth BR. Stress and the development of breast cancer: a persistent and popular link despite contrary evidence. *Cancer.* 1996; 77:1015–6. [PubMed: 8635116]
4. Duijts SFA, Zeegers MPA, Borne BV. The association between stressful life events and breast cancer risk: a meta-analysis. *Int J Cancer.* 2003; 107:1023–1029. [PubMed: 14601065]
5. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M, Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ. Chronically depressed mood and cancer risk in older persons. *J. Natl Cancer Inst.* 1998; 90:1888–1893. Stressful 6. [PubMed: 9862626]
6. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. *American Journal of Epidemiology.* 2003; 157:415–423. [PubMed: 12615606]
7. Steel JL, Geller DA, Gamblin TC, Olek MC, Carr BI. Depression, immunity, and survival in patients with hepatobiliary carcinoma. *J Clin Oncol.* 2007; 25:2397–2405. [PubMed: 17557953]
8. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a Meta-Analysis. *Cancer.* Sept 14.2009 Epub ahead of print.
9. Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC, Spiegel D. Decrease in Depression Symptoms Is Associated With Longer Survival in Patients With Metastatic Breast Cancer: A Secondary Analysis. *J Clin Oncol.* 2011; 29:413–420. [PubMed: 21149651]
10. Hamer M, Chida Y, Molloy GJ. Psychological distress and cancer mortality. *J Psychosom Res.* 2009; 66:255–258. [PubMed: 19232239]
11. Palesh O, Butler LD, Koopman C, Giese-Davis J, Carlson R, Spiegel D. Stress history and breast cancer recurrence. *J Psychosom Res.* 2007; 63:233–239. [PubMed: 17719359]
12. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. *J Clin Oncol.* 2006; 24:1105–1111. [PubMed: 16505430]
13. Sprehn GC, Chambers JE, Saykin AJ, Konski A, Johnstone PA. Decreased cancer survival in individuals separated at time of diagnosis: critical period for cancer pathophysiology? *Cancer.* 2009; 115:5108–5116. [PubMed: 19705348]
14. Kravdal O. The impact of marital status on cancer survival. *Social Sci Med.* 2001; 52:357–368.
15. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. *Psychological Med.* 2010; 40:1797–1810.
16. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? *Nat Clin Pract Oncol.* 2008; 5:466–475. [PubMed: 18493231]
17. Pinquart M, Duberstein PR. Associations of social networks with cancer mortality: a meta-analysis. *Crit Rev Oncol Hematol.* 2010; 75:122–137. [PubMed: 19604706]
18. Spiegel D, Giese-Davis J. Depression and cancer: Mechanisms and disease progression. *Biol Psychiatry.* 2003; 54:269–282. [PubMed: 12893103]

19. Petticrew M, Bell R, Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. *British Medical Journal*. 2002; 325:1066–1076. [PubMed: 12424165]
20. Antoni M, Lutgendorf S, Cole S, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The Influence of Biobehavioural Factors on Tumor Biology: Pathways and Mechanisms. *Nat Rev Cancer*. 2006; 6:240–248. [PubMed: 16498446]
21. Levy S, Herberman R, Lee J, Whiteside T, Kirkwood J, McFeeley S. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. *Nat Immun Cell Growth Regul*. 1990; 9:313–324. [PubMed: 2077396]
22. Levy S, Herberman R, Lippman M, D'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. *J Clin Oncol*. 1987; 5:348–353. [PubMed: 3546612]
23. Levy S, Herberman R, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. *Behav Med*. 1991; 17:67–75. [PubMed: 1878611]
24. Levy S, Herberman R, Maluish A, Schlein B, Lippman M. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. *Health Psychol*. 1985; 4:99–113. [PubMed: 4018006]
25. Levy, SM.; McCabe, PM.; Schneiderman, N.; Field, TM.; Skyler, JS., editors. *Stress, Coping and Disease*. Lawrence Erlbaum Associates; Hillsdale, NJ: 1991. Behavioral and immunological host factors in cancer risk; p. 237-253.
26. Glaser R, Thorn B, Tarr K, Kiecolt-Glaser J, D'Ambrosio S. Effects of stress on methy-transferase synthesis: An important DNA repair enzyme. *Health Psychol*. 1985; 4:403–412. [PubMed: 4076116]
27. Kiecolt-Glaser JK, Stephens RE, Lipetz PD, Speicher CE, Glaser R. Distress and DNA repair in human lymphocytes. *J Behav Med*. 1985; 8:311. [PubMed: 2936891]
28. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. *Lancet Oncology*. 2004; 5:617–625. [PubMed: 15465465]
29. Zorilla EP, Luborsky L, McKay JR. The relationship of depression and stressors to immunological assays: a meta-analytic review. *Brain Behav Immun*. 2001; 15:199–226. [PubMed: 11566046]
30. Irwin M. Psychoneuroimmunology of depression: clinical implications. *Brain Behav Immun*. 2002; 16:1–16. [PubMed: 11846437]
31. Thornton LM, Andersen BL, Crespin TR, Carson WE. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. *Brain Behav Immun*. 2007; 21:185–194. [PubMed: 16908118]
32. Varker KA, Terrell CE, Welt M. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobulin-like receptors. *J Surg Res*. 2007; 139:36–44. [PubMed: 17292412]
33. Andersen B, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, Glaser R. Stress and immune responses after surgical treatment for regional breast cancer. *J Natl Cancer Inst*. 1998; 90:30–6. [PubMed: 9428780]
34. Blomberg BB, Alvarez JP, Diaz A, Romero MG, Lechner SC, Carver CS, Holley H, Antoni MH. Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: An exploratory study. *J Psychosom Res*. 2009; 67:369–376. [PubMed: 19837199]
35. Sephton SE, Dhabhar FS, Keuroghlian AS, Giese-Davis J, McEwen BS, Ionan AC, Spiegel D. Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. *Brain Behav Immun*. 2009; 23:1148–55. [PubMed: 19643176]
36. Von AD, Kang D, Carpenter J. Stress, optimism, and social support: Impact on immune responses in breast cancer. *Res Nurs Health*. 2007; 30:72–83. [PubMed: 17243109]
37. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. *Nat Immunol*. 2002; 3:999–1005. [PubMed: 12407407]
38. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor escape. *J Cell Physiol*. 2003; 195:346–355. [PubMed: 12704644]

39. Lutgendorf S, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. *J Clin Oncol*. 2005; 23:7105–13. [PubMed: 16192594]
40. Lutgendorf SK, Lamkin D, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine producing populations in ovarian cancer patients. *Brain Behav Immun*. 2008; 22:890–900. [PubMed: 18276105]
41. Andersen BA, Yang H-C, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LF, Young DC, Carson WE. Psychologic Intervention improves survival for breast cancer patients. *Cancer*. 2008; 113:3450–8. [PubMed: 19016270]
42. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology. *Brain Behav Immun*. 2003; 17:27–36.
43. Ben-Eliyahu S, Page GG, Yimira R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. *Int J Cancer*. 1999; 80:880–888. [PubMed: 10074922]
44. Ben-Eliyahu, S.; Shakhar, G. Psychoneuroimmunology. Ader, R.; Felten, DL.; Cohen, N., editors. Academic Press; San Diego: 2001. p. 545-564.
45. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. *Neuroimmunomodulation*. 2000; 8:154–164. [PubMed: 11124582]
46. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. *Ann. Surg. Oncol*. 2008; 15:2042–2052. [PubMed: 18398660]
47. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: Could they reduce recurrence rates in oncological patients? *Ann. Surg. Oncol*. 2003; 10:972–992. [PubMed: 14527919]
48. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. *Nat Rev Cancer*. 2003; 3:453–458. [PubMed: 12778135]
49. Folkman J. What is the evidence that tumors are angiogenesis dependant? *J Nat Cancer Inst*. 1990; 82:4–6. [PubMed: 1688381]
50. Folkman J, Klagsbrun M. Angiogenic factors. *Science*. 1987; 235:442–447. [PubMed: 2432664]
51. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science*. 1983; 219:983–985. [PubMed: 6823562]
52. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. *Nat Clin Pract Oncol*. 2008; 5:194–204. [PubMed: 18268546]
53. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. *Cancer*. 2002; 95:808–815. [PubMed: 12209725]
54. Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA 3rd, Cole SW, Lubaroff DM, Sood AK. Biobehavioral Influences on Matrix Metalloproteinase Expression in Ovarian Carcinoma. *Clin Cancer Res*. 2008; 14:6839–6846. [PubMed: 18980978]
55. Nausheen B, Carr NJ, Peveler RC, et al. Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum. *Psychosom Med*. 2010; 72:912–916. [PubMed: 20716709]
56. Sharma A, Greenman J, Sharp DM, Walker LG, Monson JR. Vascular endothelial growth factor and psychosocial factors in colorectal cancer. *Psychooncology*. 2008; 17:66–73. [PubMed: 17410522]
57. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. *Clin Cancer Res*. 2003; 9:4514–4521. [PubMed: 14555525]
58. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase MMP-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. *Cancer Res*. 2006; 66:10357–10364. [PubMed: 17079456]

59. Yang EV, Kim SJ, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. *Brain Behav Immun.* 2009; 23:267–75. [PubMed: 18996182]
60. Yang EV, Donovan EL, Benson DM, Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. *Brain Behav Immun.* 2008; 22:318–323. [PubMed: 17981009]
61. Thaker P, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic Stress Promotes Tumor Growth and Metastasis in Ovarian Carcinoma. *Nat Med.* 2006; 12:939–944. [PubMed: 16862152]
62. Lee J, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. *Clin Cancer Res.* 2009; 15:2695–2702. [PubMed: 19351748]
63. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a SRC-dependent mechanism. *J Biol Chem.* 2007; 282:29919–29926. [PubMed: 17716980]
64. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. *J Biol Chem.* 1996; 271:736–741. [PubMed: 8557680]
65. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. *Cancer.* 2005; 104:305–313. [PubMed: 15954082]
66. Lutgendorf SK, DeGeest K, Dahmouh L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW. Social Isolation is associated with Elevated Tumor Norepinephrine in Ovarian Carcinoma Patients. *Brain Behav Immun.* 2010; 25:250–5. [PubMed: 20955777]
67. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. *Carcinogenesis.* 2004; 25:1543–1549. [PubMed: 15044327]
68. Sood AK, Bhatta R, Kamat AA, et al. Stress hormone mediated invasion of ovarian cancer cells. *Clin Cancer Res.* 2006; 12:369–375. [PubMed: 16428474]
69. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. *Cancer Res.* 2001; 61:2866–2869. [PubMed: 11306460]
70. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. *Breast Cancer Res Treat.* 2003; 80:63–70. [PubMed: 12889599]
71. Yang E, Bane CM, MacCallum RC, Kiecolt-Glaser JK, Malarkey WB, Glaser R. Stress-related modulation of matrix metalloproteinase expression. *J Neuroimmunology.* 2002; 133:144–150. [PubMed: 12446017]
72. Shanmugathan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. *50:273-9, 2000. Pathol. Int.* 2000; 50:273–279. [PubMed: 10849312]
73. Yawata A, Adachi M, Okuda H, et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. *Oncogen.* 1998; 16:2681–2686.
74. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spanuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. *J Clin Invest.* 2010; 120:1515–1523. [PubMed: 20389021]
75. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. *Nat Rev Cancer.* 2004; 4:71–78. [PubMed: 14708027]

76. Sica A, Allavena P, Mantovani A. Cancer related inflammation: The macrophage connection. *Cancer Lett.* 2008; 267:204–215. [PubMed: 18448242]
77. Sica A, Rubino L, Mancino A, et al. Targeting tumour-associated macrophages. *Expert Opin Ther Targets.* 2007; 11:1219–1229. [PubMed: 17845147]
78. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour. *Eur J Cancer.* 2006; 42:717–727. [PubMed: 16520032]
79. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J Pathol.* 2002; 196:254–265. [PubMed: 11857487]
80. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell.* 2005; 7:211–217. [PubMed: 15766659]
81. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. *Oncol. Rep.* 2005; 14:425–431. [PubMed: 16012726]
82. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. *Cancer Res.* 2010; 70:7042–7052. [PubMed: 20823155]
83. Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. *J. Psychosom. Res.* 2004; 57:353–358. [PubMed: 15518669]
84. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JMG, Penedo F, Lucci JA III, Goodheart M, Lubaroff D, Farley D, Sood AK, Cole SW. Depression, Social Support, and Beta-Adrenergic Transcription Control in Human Ovarian Cancer. *Brain Behav Immun.* 2009; 23:176–183. [PubMed: 18550328]
85. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. *Nat Med.* 2000; 6:703–706. [PubMed: 10835690]
86. Simon WE, Albrecht M, Trams G, Dietel M, Holzel F. In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. *J Natl Cancer Inst.* 1984; 73:313–321. [PubMed: 6589426]
87. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. *Cancer Res.* 2000; 60:867–872. [PubMed: 10706096]
88. Antonova L, Mueller CR. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer. *Genes.Chromosomes Cancer.* 2008; 47:341–352. [PubMed: 18196591]
89. Herr I, Ucur E, Herzer Kea. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. *Cancer Res.* 2003; 63:3112–20. [PubMed: 12810637]
90. Wu W, Chaudhuri S, Brickley DR. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. *Cancer Res.* 2004; 64:1757–1764. [PubMed: 14996737]
91. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. *Cancer Biol Ther.* 2006; 5:933–940. [PubMed: 16775428]
92. Williams JB, Pang D, Delgado B, Kocherginsky M, Tretiakova M, Krausz T, Pan D, He J, McClintock MK, Conzen SD. A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. *Cancer Prev Res.* 2009; 2:850–861.
93. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. *Annals of the New York Academy of Sciences.* 2004; 1024:138–146. [PubMed: 15265778]
94. Holbrook N, Cox W, Horner H. Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon. *Cancer Research.* 1983; 43(9):4019–4025. [PubMed: 6871844]
95. Zhou J, Olsen S, Moldovan J, et al. Glucocorticoid regulation of natural cytotoxicity: Effects of cortisol on the phenotype and function of a cloned human natural killer cell line. *Cellular Immunology.* 1997; 178:108–116. [PubMed: 9225001]

96. Balkwill F, Mantovani A. Inflammation and Cancer: Back to Virchow? *Lancet*. 2001; 357:539–545. [PubMed: 11229684]
97. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. *Cancer Cell*. 2007; 12:300–301. [PubMed: 17936555]
98. Maier S, Watkins L. Cytokines for psychologists: Implications of bidirectional immune to brain communication for understanding behavior, mood, and cognition. *Psychology Rev*. 1998; 105:83–107.
99. Capuron L, Dantzer R. Cytokines and depression: The need for a new paradigm. *Brain Behav Immun*. 2003; 17:S119–S124. [PubMed: 12615197]
100. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. *TRENDS in Immunol*. 2006; 27(1):24–31. [PubMed: 16316783]
101. Pyter LM, Pinos V, Galang JA, McClintock MK, Prendergast BJ. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. *Proc Nat Acad Sci USA*. 2009; 106:9069–9074. [PubMed: 19451634]
102. Lamkin DM, Lutgendorf SK, Lubaroff DM, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: Modulation by social housing. *Brain Behav Immun*. in press.
103. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. *Psychosom Med*. 2002; 64:604–611. [PubMed: 12140350]
104. Collado-Hidalgo A, Bower ME, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. *Clin Cancer Res*. 2006; 12:2759–2766. [PubMed: 16675568]
105. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. *Psychoneuroendocrino*. 2005; 30:92–100.
106. Weinrib A, Sephton SE, DeGeest K, et al. Diurnal cortisol dysregulation: Links with depression and functional disability in women with ovarian cancer. *Cancer*. 2010; 116:4410–4419. [PubMed: 20564155]
107. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients. *J Clin Oncol*. 2008; 26:4820–7. [PubMed: 18779606]
108. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. *Am J Psychiatry*. 2001; 158:1252–57. [PubMed: 11481159]
109. Jehn CF, Kuehnhardt D, Bartholomae A, et al. Biomarkers of depression in cancer patients. *Cancer*. 2006; 107:2723–29. [PubMed: 17036362]




Figure 1.

Effects of stress and psychosocial processes on the tumor microenvironment. The stress response results in activation of the autonomic nervous system and the hypothalamic-pituitary adrenal axis. Factors released from these pathways can have direct effects on the tumor microenvironment, resulting in a favorable environment for tumor growth and progression. These dynamics can also adversely affect patient quality of life. CRH, corticotropin releasing hormone; ACTH, adrenocorticotrophic hormone; NK natural killer; T-regs, regulatory T-cells; TAM, tumor associated macrophages; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor; IL, interleukin; STAT3, signal transducer and activator of transcription factor-3; QOL, quality of life. Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved. Lutgendorf S., et al. *J Clin Oncology*, 28 (26) 2010, 4094-9.